We are establishing a number of resources to give scientists access to the first-rate technology and expertise required for measuring epigenetic processes on the genomic scale, and for developing novel reagents and approaches to interrogate the state of chromatin.

Epigenetics Technology Innovation Lab

Recent technological advancements have made it possible to undertake comprehensive epigenomic studies to enable physicians and researchers to examine disease pathology in systematic and comprehensive ways. The Epigenetics Technology Innovation Lab is responsible for the development and implementation of genome-wide assays focused on the assessment of histone modifications, DNA methylation, and chromatin accessibility, among other approaches. The resource gives MSK researchers access to the best epigenomic technologies available.

Computational Epigenetics Lab

We are establishing a group of experts in computational biology and bioinformatics who specialize in analyzing and integrating epigenomic data. Working together with other groups at MSK — including computational scientists in the Computational Biology Program, the Computational Oncology Service, and the Bioinformatics Core Facility — this core team will help establish methods for comprehensive genomic and epigenomic assessment of cancer cells.

Preclinical Interface Platform

CER scientists will work closely with MSK’s core facilities for Antitumor Assessment and RNA Interference to create a platform to develop preclinical models, new therapeutic approaches, and chemical biology tools to target tumors at the epigenetic level. The platform will allow us to establish libraries of potent and specific small molecules that target chromatin-regulatory complexes. It will also help guide preclinical studies of promising molecules that have the potential to ultimately be moved to clinical assessment in patients.